[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594626":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":45,"responsibleParty":96,"collaborators":25,"id":98,"slug":25,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":99,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":25,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Erasca, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ERAS-4001 Monotherapy Dose Optimization.","EXPERIMENTAL","Escalating doses of ERAS-4001 administered orally.",[13],"Drug: ERAS-4001",{"label":15,"type":10,"description":16,"interventionNames":17},"ERAS-4001 Combination Dose Optimization","ERAS-4001 administered orally with another investigational agent.",[18],"Drug: ERAS-4001 in combination",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ERAS-4001","ERAS-4001 Administered orally",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"ERAS-4001 in combination","ERAS-4001 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.",[15],[31,32],"Keytruda (pembrolizumab)","Vectibix (panitumumab)",[34],{"name":35,"affiliation":5,"role":36},"Gerri Lee","STUDY_DIRECTOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":25,"email":42},"Erasca Clinical Team","CONTACT","+1-858-465-6511","clinicaltrials@erasca.com",{"name":44,"role":40,"phone":25,"phoneExt":25,"email":25},"Les Brail, Study Director, PhD",[46,59,69,78,86],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":25},"Sarah Cannon Research Institute (SCRI) Oncology Partners","RECRUITING","Nashville","Tennessee","32703","United States",{"type":54,"coordinates":55},"Point",[56,57],-86.78444,36.16589,{"lat":57,"lon":56},{"facility":60,"status":48,"city":61,"state":62,"zip":63,"country":52,"cosmosGeoPoint":64,"geoPoint":68,"contacts":25},"The University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":54,"coordinates":65},[66,67],-95.36327,29.76328,{"lat":67,"lon":66},{"facility":70,"status":48,"city":71,"state":62,"zip":72,"country":52,"cosmosGeoPoint":73,"geoPoint":77,"contacts":25},"NEXT Oncology","Irving","75039",{"type":54,"coordinates":74},[75,76],-96.94889,32.81402,{"lat":76,"lon":75},{"facility":70,"status":48,"city":79,"state":62,"zip":80,"country":52,"cosmosGeoPoint":81,"geoPoint":85,"contacts":25},"San Antonio","78229",{"type":54,"coordinates":82},[83,84],-98.49363,29.42412,{"lat":84,"lon":83},{"facility":87,"status":48,"city":88,"state":89,"zip":90,"country":52,"cosmosGeoPoint":91,"geoPoint":95,"contacts":25},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":54,"coordinates":92},[93,94],-122.33207,47.60621,{"lat":94,"lon":93},{"type":97,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100594626",false,"NCT07021898","A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.","A Phase 1 First-in-Human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-4001 Monotherapy and in Combination in Patients With Advanced Solid Tumors","BOREALIS-1","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Willing and able to give written informed consent\n* Pathological documentation of tumor type and mutation prior to the first dose of study drug(s)\n* There is no available standard systemic therapy available for the patient's tumor histology and\u002For molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy\n* Able to swallow oral medication\n* Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* Adequate cardiovascular, hematological, liver, and renal function\n* Willing to comply with all protocol-required visits, assessments, and procedures\n\nExclusion Criteria:\n\n* Previous treatment with a RAS inhibitor\n* Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-4001\n* Received prior palliative radiation within 14 days of Cycle 1, Day 1\n* Have primary central nervous system (CNS) tumors\n* Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption\n* Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs\n* Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial","ALL","18 Years","99 Years",{"count":109,"type":110},200,"ESTIMATED","INTERVENTIONAL",[113],"PHASE1","The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.",[116],"Metastatic Solid Tumors",[118,119,120,121,122,123,124,125,126,127,128],"Solid Tumor","Advanced Solid Tumor","Solid malignancies","Targeted therapy","Molecular alterations","pembrolizumab","Keytruda","panitumumab","Vectibix","Metastatic solid tumor","Neoplasms","2025-12-02",{"date":131,"type":132},"2025-12-03","ACTUAL",{"date":134,"type":132},"2025-08-06",{"date":136,"type":110},"2028-12",{"name":5,"class":6},5]